ReviewCurrent opinion in lipidology2014
Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field.
Review in Current opinion in lipidology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.BMC gastroenterology · 2015Trial
- Examining Prenylated Xanthones as Potential Inhibitors Against Ketohexokinase C Isoform for the Treatment of Fructose-Driven Metabolic Disorders: An Integrated Computational Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring Marine-Derived Compounds: In Silico Discovery of Selective Ketohexokinase (KHK) Inhibitors for Metabolic Disease Therapy.Marine drugs · 2024Article
- Nutritional Interventions, Probiotics, Synbiotics and Fecal Microbiota Transplantation in Steatotic Liver Disease : Pediatric Fatty Liver and Probiotics.Advances in experimental medicine and biology · 2024Review
- Article
- High Fructose Intake During Pregnancy in Rats Influences the Maternal Microbiome and Gut Development in the Offspring.Frontiers in genetics · 2018Article
- Nonhuman Primates and Translational Research-Cardiovascular Disease.ILAR journal · 2017Review
- Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis.Nutrients · 2017Article
- miR-149 controls non-alcoholic fatty liver by targeting FGF-21.Journal of cellular and molecular medicine · 2016Article
- Hepatic glucose and lipid metabolism.Diabetologia · 2016Review
- Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study.The Journal of pediatrics · 2016Article
- Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats.Nutrition & metabolism · 2016Article
- Fructose Malabsorption in Systemic Sclerosis.Medicine · 2015Observational
- Assessment of cardiometabolic risk in children in population studies: underpinning developmental origins of health and disease mother-offspring cohort studies.Journal of nutritional science · 2015Review
- Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?Diabetologia · 2014Article
- Epigenetic effects of human breast milk.Nutrients · 2014Review
- Pediatric Fatty Liver Disease.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and it has overlapping pathogenesis with diabetes and cardiovascular disease. Reviewed here are recent advances in understanding the contribution of diet and selected nutrients to NAFLD. RECENT
findingsTo understand the effect of diet, the microbiome must be considered because it is the interface of diet and the liver. Early studies suggest that the characteristic of the microbiota is altered in NAFLD. Fructose is a lipogenic carbohydrate that contributes to insulin resistance, hypertriglyceridemia and appears to be associated with the severity of NAFLD. Fructose absorption and malabsorption may alter the microbiota and could be mediating effects on the liver. Lipids also have potent microbiome interactions and could contribute to the benefit of diets emphasizing lipid changes. Several new studies demonstrate that the Mediterranean diet and 'lifestyle change' are effective in modestly improving NAFLD. A new study of 'lifestyle' in children showed simultaneous improvement in cardiovascular disease risk measurements and hepatic steatosis. SUMMARY: Current data supports limiting sugar in the diet and 'lifestyle change' as a first-line treatment for NAFLD; however, the benefits from these appear to be modest. The effects of diet on the liver are mediated through the microbiome and expansion of research in this area is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.